within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC08_Canakinumab;
model Canakinumab 
   extends Pharmacolibrary.Drugs.ATC.L.L04AC08;

  annotation(Documentation(
    info ="<html><body><p>Canakinumab is a human monoclonal antibody targeting interleukin-1 beta (IL-1β), used in the treatment of autoinflammatory diseases such as cryopyrin-associated periodic syndromes (CAPS), systemic juvenile idiopathic arthritis (sJIA), and Still's disease. It is an approved immunosuppressive agent, primarily administered to reduce inflammation.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult and pediatric patients with autoinflammatory conditions. Data from observed clinical trials including healthy volunteers and patients with CAPS.</p><h4>References</h4><ol><li><p>Chakraborty, A, Tannenbaum, S, Rordorf, C, Lowe, PJ, Floch, D, Gram, H, &amp; Roy, S (2012). Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. <i>Clinical pharmacokinetics</i> 51(6) e1–e18. DOI:<a href=&quot;https://doi.org/10.2165/11599820-000000000-00000&quot;>10.2165/11599820-000000000-00000</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22550964/&quot;>https://pubmed.ncbi.nlm.nih.gov/22550964</a></p></li><li><p>Hoy, SM (2015). Canakinumab: a review of its use in the management of systemic juvenile idiopathic arthritis. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 29(2) 133–142. DOI:<a href=&quot;https://doi.org/10.1007/s40259-015-0123-8&quot;>10.1007/s40259-015-0123-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25822149/&quot;>https://pubmed.ncbi.nlm.nih.gov/25822149</a></p></li><li><p>Chakraborty, A, Van, LM, Skerjanec, A, Floch, D, Klein, UR, Krammer, G, Sunkara, G, &amp; Howard, D (2013). Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. <i>Journal of clinical pharmacology</i> 53(12) 1240–1251. DOI:<a href=&quot;https://doi.org/10.1002/jcph.162&quot;>10.1002/jcph.162</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24122883/&quot;>https://pubmed.ncbi.nlm.nih.gov/24122883</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Canakinumab;
